Mayo Clinic has made a historic investment to help the world respond to COVID-19, leading the way in research, testing, and industry partnerships to help make needed therapies available to those who need it most.
Mayo Clinic's COVID-19 Response
Molecular tests performed as of July 1
States sending COVID-19 testing to Mayo Clinic
Infectious disease physicians and scientists
Weeks it took Mayo to develop a PCR LDT
Available Testing to Support COVID-19
BioPharma Diagnostics is providing the following tests to support research for both vaccine and therapy development. Our testing enables research by providing key information to understand disease status among patient populations. Links go to specifics in the Mayo Clinic Laboratories tests menu.
Useful for detection of COVID-19 due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Useful for detection of IgG-class antibodies against SARS-CoV-2, the virus that causes COVID-19.
Neutralizing Antibody Test
The new test measures the level of neutralizing antibodies against SARS-CoV-2.
COVID-19 Related Testing
Severe COVID-19 patients are characterized by a higher baseline IL-6 level compared to non-severe infections. In critically ill patients with COVID-19, IL-6 levels were almost tenfold higher. While it is not clear whether elevation in IL-6 has a causal association with pro-inflammatory damage of the lungs or is just a consequence of the lung infection, attempts at blocking IL-6 by using monoclonal antibodies directed against IL-6 receptors have garnered interested as a potential therapeutic option
Hydroxychloroquine (HCQ) is an antimalarial drug that is currently FDA-approved for systemic lupus erythematosus (SLE), malaria, and rheumatoid arthritis. In laboratory tests, hydroxychloroquine can prevent the SARS-CoV and SARS-CoV-2 viruses from attaching to and entering cells. If these antiviral abilities work the same way in animals and humans, the drug could be used to treat patients and limit the number of COVID-19 deaths. Dosage recommendations vary based on clinical indications, and the long terminal elimination half-life of HCQ should be considered. Accumulation of HCQ occurs in multiple organs and can result in mild to severe toxicity. Therapeutic drug monitoring (TDM) can be used as an objective measure to effectively manage patients prescribed HCQ
In addition to the risk of toxicity from HCQ, hemolysis has been reported in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency during the post-approval use of hydroxychloroquine sulfate tablets, USP. While patients receiving HCQ do not routinely need G6PD levels checked before initiating therapy, testing should be considered in patients who are of Mediterranean, African, or Asian descent
One of the most characteristic changes in COVID-19 patients is lymphopenia. In addition to total lymphocytes, T cells (CD4+ T cells, CD8+ T cells), B cells, and natural killer (NK) cells are all decreased in COVID-19 patients compared to healthy controls. These cell counts correlate with severity and also normalize in post-treatment patients who recover. For severe cases of COVID-19, further analysis may be required and experts in Mayo Clinic’s Cellular and Molecular Immunology Laboratory are available for further discussion.